Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion

NCT02754999 is registered in ClinicalTrials.gov with Prolong Pharmaceuticals as lead sponsor.

NCT NCT02754999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02754999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Lead sponsor
Prolong Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2016
Completion date
May 17, 2017
Enrollment
103 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

acute anemia